J.M. Lange

Latest

• Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance: response
• Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine
• [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection]
• Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort
• Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study
• Protease inhibitors and non-nucleoside reverse transcriptase inhibitors have a comparable effect on the CD4 cell change after switching to tenofovir-based regimens
• Cytomegalovirus rather than HIV triggers the outgrowth of effector CD8+CD45RA+CD27- T cells in HIV-1-infected children
• Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy
• The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART
• Are adverse events of nevirapine and efavirenz related to plasma concentrations?
• Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1
• Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz
• Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients
• Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study
• Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy
• Use of composite end points to measure clinical events
• A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients